Stay updated with breaking news from Rhizen Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Rhizen Pharma reports encouraging initial results from an ongoing phase II trial to evaluate Tenalisib (RP6530; isoform selective dual PI3K d/? inhibitor with additional SIK3 inhibitory activity)
Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen's differ
Rhizen Pharma announces presentations at AACR showcasing its differentiated clinical stage PARP and DHODH programs Preclinical data on Rhizen's differentiated PARP inhibitor RP12146, indicates
Umbralisib has peak market size potential to reach $1 billion - $1.5 billion
Rhizen Pharmaceuticals gets USFDA nod for cancer drug Umbralisib February 09, 2021 In a first, Indian scientists develop oral drug for relapsed or refractory MZL, FL In a major breakthrough in cancer treatment, Alembic Pharmaceutical’s co-owned Rhizen Pharmaceuticals has received US drug regulator - US Food and Drug Administration (USFDA)’s approval for novel next generation oral inhibitor of phosphoinositide 3 kinase (PI3K) delta - Umbralisib for treatment of relapsed or refractory marginal zone lymphoma (MZL), follicular lymphoma (FL). Umbralisib will be marketed by Nasdaq-listed TG The...